Fig. 5From: A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthmaPercent (%) change in post-dose FEV1 compared to pre-dose, by dosing day. The change in median FEV1 following DAS181 versus placebo dosing was not statistically different either overall (p = 0.45) or by dosing dayBack to article page